CD9 expression rivals IDH mutation as a prognostic marker in glioma: a novel nomogram approach

PurposeGlioma remains a lethal malignancy with limited prognostic biomarkers. This study evaluates the prognostic significance and functional mechanisms of tetraspanin CD9 in glioma to establish its clinical relevance and identify therapeutic strategies.MethodsMulti-omics analyses were performed usi...

Full description

Saved in:
Bibliographic Details
Main Authors: Yue Peng, Qiang Ji, Xiangyu Guo, Weichunbai Zhang, Zixuan Yang, Wenbin Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Neurology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2025.1507443/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850190531733225472
author Yue Peng
Qiang Ji
Qiang Ji
Xiangyu Guo
Weichunbai Zhang
Zixuan Yang
Wenbin Li
Wenbin Li
author_facet Yue Peng
Qiang Ji
Qiang Ji
Xiangyu Guo
Weichunbai Zhang
Zixuan Yang
Wenbin Li
Wenbin Li
author_sort Yue Peng
collection DOAJ
description PurposeGlioma remains a lethal malignancy with limited prognostic biomarkers. This study evaluates the prognostic significance and functional mechanisms of tetraspanin CD9 in glioma to establish its clinical relevance and identify therapeutic strategies.MethodsMulti-omics analyses were performed using 1,033 glioma samples from TCGA and CGGA cohorts. A CD9-integrated nomogram was developed via Cox regression. Two-sample Mendelian randomization (MR) assessed the causal link between CD9 expression and glioma risk using IVW, MR-Egger, and WM methods. KEGG enrichment analysis identified biological pathways. Single-cell RNA sequencing from 20 glioblastoma cases was analyzed using CellChat and Monocle3 to explore CD9-mediated cell communication and lineage transitions. Protein-protein interaction (PPI) networks were constructed via STRING and GeneMANIA, and drug predictions were performed using DsigDB.ResultsCD9 overexpression was an independent predictor of poor survival (HR = 1.28, 95% CI 1.03–1.58). The CD9-based nomogram showed high prognostic accuracy (CGGA: C-index = 0.805 ± 0.01, TCGA: C-index = 0.859 ± 0.02). MR confirmed a causal association between CD9 and glioma risk (IVW OR = 1.33, p < 0.05) with no horizontal pleiotropy. CD9 regulated glioma progression via calcium signaling and synaptic pathways, interacting with ITGB1 and CD81. Single-cell analysis revealed CD9-driven NPC-to-OPC transdifferentiation, linked to tumor proliferation. Emetine was identified as a potential CD9-targeting drug.ConclusionCD9 is a prognostic biomarker in glioma, with causal evidence linking its overexpression to tumor development. Its integration into risk models enhances prognostic precision, while drug screening highlights emetine as a potential therapy.
format Article
id doaj-art-ea406cce4ca84c808f01445dcd327db8
institution OA Journals
issn 1664-2295
language English
publishDate 2025-04-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Neurology
spelling doaj-art-ea406cce4ca84c808f01445dcd327db82025-08-20T02:15:15ZengFrontiers Media S.A.Frontiers in Neurology1664-22952025-04-011610.3389/fneur.2025.15074431507443CD9 expression rivals IDH mutation as a prognostic marker in glioma: a novel nomogram approachYue Peng0Qiang Ji1Qiang Ji2Xiangyu Guo3Weichunbai Zhang4Zixuan Yang5Wenbin Li6Wenbin Li7Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaDepartment of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaNational Institute for Data Science in Health and Medicine, Capital Medical University, Beijing, ChinaNational Institute for Data Science in Health and Medicine, Capital Medical University, Beijing, ChinaNational Institute for Data Science in Health and Medicine, Capital Medical University, Beijing, ChinaNational Institute for Data Science in Health and Medicine, Capital Medical University, Beijing, ChinaDepartment of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaNational Institute for Data Science in Health and Medicine, Capital Medical University, Beijing, ChinaPurposeGlioma remains a lethal malignancy with limited prognostic biomarkers. This study evaluates the prognostic significance and functional mechanisms of tetraspanin CD9 in glioma to establish its clinical relevance and identify therapeutic strategies.MethodsMulti-omics analyses were performed using 1,033 glioma samples from TCGA and CGGA cohorts. A CD9-integrated nomogram was developed via Cox regression. Two-sample Mendelian randomization (MR) assessed the causal link between CD9 expression and glioma risk using IVW, MR-Egger, and WM methods. KEGG enrichment analysis identified biological pathways. Single-cell RNA sequencing from 20 glioblastoma cases was analyzed using CellChat and Monocle3 to explore CD9-mediated cell communication and lineage transitions. Protein-protein interaction (PPI) networks were constructed via STRING and GeneMANIA, and drug predictions were performed using DsigDB.ResultsCD9 overexpression was an independent predictor of poor survival (HR = 1.28, 95% CI 1.03–1.58). The CD9-based nomogram showed high prognostic accuracy (CGGA: C-index = 0.805 ± 0.01, TCGA: C-index = 0.859 ± 0.02). MR confirmed a causal association between CD9 and glioma risk (IVW OR = 1.33, p < 0.05) with no horizontal pleiotropy. CD9 regulated glioma progression via calcium signaling and synaptic pathways, interacting with ITGB1 and CD81. Single-cell analysis revealed CD9-driven NPC-to-OPC transdifferentiation, linked to tumor proliferation. Emetine was identified as a potential CD9-targeting drug.ConclusionCD9 is a prognostic biomarker in glioma, with causal evidence linking its overexpression to tumor development. Its integration into risk models enhances prognostic precision, while drug screening highlights emetine as a potential therapy.https://www.frontiersin.org/articles/10.3389/fneur.2025.1507443/fullGliomaCD9Cox proportional hazards regressionMendelian randomizationSingle-cell analysis
spellingShingle Yue Peng
Qiang Ji
Qiang Ji
Xiangyu Guo
Weichunbai Zhang
Zixuan Yang
Wenbin Li
Wenbin Li
CD9 expression rivals IDH mutation as a prognostic marker in glioma: a novel nomogram approach
Frontiers in Neurology
Glioma
CD9
Cox proportional hazards regression
Mendelian randomization
Single-cell analysis
title CD9 expression rivals IDH mutation as a prognostic marker in glioma: a novel nomogram approach
title_full CD9 expression rivals IDH mutation as a prognostic marker in glioma: a novel nomogram approach
title_fullStr CD9 expression rivals IDH mutation as a prognostic marker in glioma: a novel nomogram approach
title_full_unstemmed CD9 expression rivals IDH mutation as a prognostic marker in glioma: a novel nomogram approach
title_short CD9 expression rivals IDH mutation as a prognostic marker in glioma: a novel nomogram approach
title_sort cd9 expression rivals idh mutation as a prognostic marker in glioma a novel nomogram approach
topic Glioma
CD9
Cox proportional hazards regression
Mendelian randomization
Single-cell analysis
url https://www.frontiersin.org/articles/10.3389/fneur.2025.1507443/full
work_keys_str_mv AT yuepeng cd9expressionrivalsidhmutationasaprognosticmarkeringliomaanovelnomogramapproach
AT qiangji cd9expressionrivalsidhmutationasaprognosticmarkeringliomaanovelnomogramapproach
AT qiangji cd9expressionrivalsidhmutationasaprognosticmarkeringliomaanovelnomogramapproach
AT xiangyuguo cd9expressionrivalsidhmutationasaprognosticmarkeringliomaanovelnomogramapproach
AT weichunbaizhang cd9expressionrivalsidhmutationasaprognosticmarkeringliomaanovelnomogramapproach
AT zixuanyang cd9expressionrivalsidhmutationasaprognosticmarkeringliomaanovelnomogramapproach
AT wenbinli cd9expressionrivalsidhmutationasaprognosticmarkeringliomaanovelnomogramapproach
AT wenbinli cd9expressionrivalsidhmutationasaprognosticmarkeringliomaanovelnomogramapproach